{"entity":{"id":"yonsei-mced-wgs","kind":"trial","name":"Yonsei whole-genome cell-free DNA multi-cancer platform study","aka":[],"tldr":"A South Korean study building a multi-cancer blood test from whole-genome sequencing of circulating DNA.","summary":"Yonsei whole-genome cell-free DNA multi-cancer platform study (NCT06231953) is an observational study sponsored by Yonsei University. It aims to establish a multi-cancer early detection platform through whole-genome sequencing of circulating DNA.\n\nThe registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 4,000 participants, a start on 13 October 2022 and primary completion expected in December 2026.","status":"recruiting","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT06231953","url":"https://clinicaltrials.gov/study/NCT06231953"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06231953","phase":"observational","setting":"People with invasive cancer and healthy volunteers at up to 10 South Korean institutions","sponsor":"Yonsei University","started":"2022-10-13","startedType":"actual","enrolled":4000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/yonsei-mced-wgs/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"trial":[{"id":"yonsei-mced-wgs-2","kind":"trial","name":"Yonsei whole-genome cell-free DNA multi-cancer platform: development, validation and confirmation","route":"/trials/yonsei-mced-wgs-2/"}]}}